SCHEDULE 13D/A: Major Shareholder Corrects Ownership Stake in Dermata Therapeutics

Gerald T. Proehl and Proehl Investment Ventures LLC filed an amended Schedule 13D to correct their reported beneficial ownership percentage in Dermata Therapeutics, Inc. to 13.3% based on an updated outstanding share count.

Summary

• This document is Amendment No. 7 to the Schedule 13D filing for Dermata Therapeutics, Inc.
• The primary purpose of this amendment is to correct the previously reported number of the Issuer's outstanding Common Stock shares and the beneficial ownership percentage of the Reporting Persons, which was incorrectly stated in Amendment No. 6 filed on April 3, 2025.
• The filing does not result from any new transactions in the securities of Dermata Therapeutics, Inc.
• Gerald T. Proehl, President and Chief Executive Officer, and Proehl Investment Ventures LLC (PIV) are the reporting persons.
• As of March 27, 2025, Mr. Proehl beneficially owns an aggregate of 804,098 shares of Common Stock, representing 13.3% of the Issuer's outstanding Common Stock.
• Mr. Proehl's beneficial ownership includes 247 shares held directly, 799,508 shares held by PIV, and 855 shares held by certain trusts for which he is trustee, along with associated stock options and warrants exercisable within 60 days.
• Proehl Investment Ventures LLC beneficially owns an aggregate of 799,624 shares of Common Stock, also representing 13.3% of the Issuer's outstanding Common Stock.
• The beneficial ownership percentages are calculated based on 6,032,648 shares of Common Stock outstanding as of March 27, 2025.
• There were no purchases or sales of Common Stock or convertible securities by the Reporting Persons during the sixty days prior to March 27, 2025.

Sentiment

Score: 5

Explanation: Neutral, as the document is a factual correction of a regulatory filing and does not contain new operational or financial information that would impact sentiment positively or negatively.

Positives

• The filing provides updated and corrected information regarding significant beneficial ownership, enhancing transparency and accuracy of public records.

Negatives

• The necessity for a correction indicates a previous reporting error, which could suggest minor administrative oversight in prior filings.

Future Outlook

This filing is a correction of historical beneficial ownership data and does not contain forward-looking statements or guidance regarding the company's future operations, financial performance, or strategic direction.

Management Comments

• The filing is a standard regulatory update signed by Gerald T. Proehl, President and Chief Executive Officer, and does not contain specific management commentary beyond the factual correction of beneficial ownership information.

Industry Context

This Schedule 13D amendment is a routine regulatory filing for a significant shareholder and does not provide insights into broader industry trends or the competitive landscape for Dermata Therapeutics, Inc., which operates in the biotechnology or pharmaceutical sector, likely focused on dermatological treatments.

Comparison to Industry Standards

• This filing is a regulatory disclosure of beneficial ownership and does not contain financial or operational results that can be compared to industry benchmarks or specific comparable companies/projects. Its sole purpose is to correct previously reported ownership data.

Stakeholder Impact

• Shareholders: Provides corrected information on a significant shareholder's ownership stake, ensuring transparency and accuracy of public records, which is crucial for investment decisions.

Next Steps

• The document does not specify any future actions, events, or milestones for the company or the reporting persons beyond the filing of this correction.

Key Dates

Keywords

Dermata Therapeutics, Schedule 13D, Beneficial Ownership, Gerald T. Proehl, Proehl Investment Ventures, Common Stock, SEC Filing, Shareholder, Ownership Stake